featured
Impact of Anti-VEGF Biosimilars on Patient and Overall Healthcare Costs
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Ophthalmology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The Biosimilar Paradox: How Anti-VEGF Biosimilars will Increase Patient and Overall Healthcare Costs
Ophthalmology 2023 Apr 26;[EPub Ahead of Print], C Zhang, S Friedman, P Mruthyunjaya, R ParikhFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.